Fig. 7
From: T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Targeted delivery of a TLR7/8 agonist (R848) to PD-1-expressing cells extends survival and sensitizes tumors to anti-PD-1. C57BL/6 mice were inoculated subcutaneously with 200,000 MC38 cells. a, b Starting on day 5, nanoparticles or free drugs were administered intravenously every other day up to a total of 10 injections. The dose was 20 μg of anti-PD-1 and 60 μg of R848 per injection. Tumor volume and animal survival were monitored to assess anti-tumor efficacy. c, d Nanoparticles or free drugs (20 μg of anti-PD-1 and 60 μg of R848) were administered intravenously on days 5, 7, and 9 post-tumor inoculation to activate the innate immune system and thereby inflame the tumor. On days 11, 14, and 17, anti-PD-1 antibody (clone 29 F.1A12, 200 μg) was injected intraperitoneally, as this IgG is typically administered. Tumor volume and animal survival were monitored to assess for efficacy (n = 6–7, mean ± s.e.m; *p < 0.05; ***p < 0.001, Mantel-Cox test)
